ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
1,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
4,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
4,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
5,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
6,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
7,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
7,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
7,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
7,4,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
7,5,Respiration abnormal,Breathing abnormalities,Respiratory disorders NEC,Resp,N
7,6,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
7,7,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
8,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
8,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
8,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
8,4,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
8,5,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
8,6,Respiration abnormal,Breathing abnormalities,Respiratory disorders NEC,Resp,N
8,7,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
8,8,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
9,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
10,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
11,1,Radiation proctitis,Radiation injuries,Injuries by physical agents,Inj&P,N
11,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
12,1,Factor IX inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
13,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
13,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
13,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
13,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
13,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
14,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
15,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
15,2,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
16,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
17,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
17,2,Spontaneous haemorrhage,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
18,1,Infusion site oedema,Infusion site reactions,Administration site reactions,Genrl,N
18,2,Infusion site pruritus,Infusion site reactions,Administration site reactions,Genrl,N
18,3,Infusion site rash,Infusion site reactions,Administration site reactions,Genrl,N
18,4,Infusion site swelling,Infusion site reactions,Administration site reactions,Genrl,N
19,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
20,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
21,1,Intermenstrual bleeding,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
21,2,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
22,1,Factor IX inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
23,1,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
24,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
24,2,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
25,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
26,1,Factor IX inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
27,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
27,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
28,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
29,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
30,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
30,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
30,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
30,4,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
30,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
31,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
32,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
33,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
34,1,Factor IX inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
35,1,Factor IX inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
36,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
37,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
37,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
